Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Haley B Naik

Showing results (81-90 of 106) with videos related to

Pageof 11
Sort By:
JCI Insight|October 24, 2022
Immunopathogenesis of hidradenitis suppurativa and response to anti-TNF-α therapyMargaret M Lowe, Haley B Naik, Sean Clancy, et al.
JCI Insight|December 19, 2023
Tertiary lymphoid structures sustain cutaneous B cell activity in hidradenitis suppurativaMargaret M Lowe, Jarish N Cohen, Madison I Moss, et al.
Journal of the American Academy of Dermatology|November 17, 2025
Bimekizumab demonstrated a favorable safety profile and high levels of efficacy with up to 2 years of treatment in patients with moderate to severe hidradenitis suppurativa: Pooled results from two phase 3 randomized, controlled trials and their open-label extensionChristopher J Sayed, Brian Kirby, Amit Garg, et al.
Experimental Dermatology|February 11, 2025
The Inflammatory Landscape of a Whole-Tissue Explant Model of Hidradenitis SuppurativaPhoebe E Leboit, Dhara U Patel, Jarish N Cohen, et al.
Journal of the American Academy of Dermatology|September 18, 2022
Anakinra for refractory pustular psoriasis: A phase II, open-label, dose-escalation trialHaley B Naik, Dominique C Pichard, Daniella M Schwartz, et al.
Journal of the American Academy of Dermatology|March 16, 2019
North American clinical management guidelines for hidradenitis suppurativa: A publication from the United States and Canadian Hidradenitis Suppurativa Foundations: Part II: Topical, intralesional, and systemic medical managementAli Alikhan, Christopher Sayed, Afsaneh Alavi, et al.
Journal of the American Academy of Dermatology|March 16, 2019
North American clinical management guidelines for hidradenitis suppurativa: A publication from the United States and Canadian Hidradenitis Suppurativa Foundations: Part I: Diagnosis, evaluation, and the use of complementary and procedural managementAli Alikhan, Christopher Sayed, Afsaneh Alavi, et al.
Frontiers in Medicine|November 24, 2018
Perspective From the 5th International Pemphigus and Pemphigoid Foundation Scientific ConferenceJinmin Lee, Victoria P Werth, Russell P Hall, et al.
JAMA Dermatology|February 24, 2021
Hidradenitis Suppurativa in the Pediatric Population: An International, Multicenter, Retrospective, Cross-sectional Study of 481 Pediatric PatientsCarmen Liy-Wong, Mary Kim, A Yasmine Kirkorian, et al.
Arteriosclerosis, Thrombosis, and Vascular Biology|October 10, 2015
Severity of Psoriasis Associates With Aortic Vascular Inflammation Detected by FDG PET/CT and Neutrophil Activation in a Prospective Observational StudyHaley B Naik, Balaji Natarajan, Elena Stansky, et al.
Pageof 11

Showing results (81-90 of 106) with videos related to

Sort By:
Pageof 11
JCI Insight|October 24, 2022
Immunopathogenesis of hidradenitis suppurativa and response to anti-TNF-α therapyMargaret M Lowe, Haley B Naik, Sean Clancy, et al.
JCI Insight|December 19, 2023
Tertiary lymphoid structures sustain cutaneous B cell activity in hidradenitis suppurativaMargaret M Lowe, Jarish N Cohen, Madison I Moss, et al.
Journal of the American Academy of Dermatology|November 17, 2025
Bimekizumab demonstrated a favorable safety profile and high levels of efficacy with up to 2 years of treatment in patients with moderate to severe hidradenitis suppurativa: Pooled results from two phase 3 randomized, controlled trials and their open-label extensionChristopher J Sayed, Brian Kirby, Amit Garg, et al.
Experimental Dermatology|February 11, 2025
The Inflammatory Landscape of a Whole-Tissue Explant Model of Hidradenitis SuppurativaPhoebe E Leboit, Dhara U Patel, Jarish N Cohen, et al.
Journal of the American Academy of Dermatology|September 18, 2022
Anakinra for refractory pustular psoriasis: A phase II, open-label, dose-escalation trialHaley B Naik, Dominique C Pichard, Daniella M Schwartz, et al.
Journal of the American Academy of Dermatology|March 16, 2019
North American clinical management guidelines for hidradenitis suppurativa: A publication from the United States and Canadian Hidradenitis Suppurativa Foundations: Part II: Topical, intralesional, and systemic medical managementAli Alikhan, Christopher Sayed, Afsaneh Alavi, et al.
Journal of the American Academy of Dermatology|March 16, 2019
North American clinical management guidelines for hidradenitis suppurativa: A publication from the United States and Canadian Hidradenitis Suppurativa Foundations: Part I: Diagnosis, evaluation, and the use of complementary and procedural managementAli Alikhan, Christopher Sayed, Afsaneh Alavi, et al.
Frontiers in Medicine|November 24, 2018
Perspective From the 5th International Pemphigus and Pemphigoid Foundation Scientific ConferenceJinmin Lee, Victoria P Werth, Russell P Hall, et al.
JAMA Dermatology|February 24, 2021
Hidradenitis Suppurativa in the Pediatric Population: An International, Multicenter, Retrospective, Cross-sectional Study of 481 Pediatric PatientsCarmen Liy-Wong, Mary Kim, A Yasmine Kirkorian, et al.
Arteriosclerosis, Thrombosis, and Vascular Biology|October 10, 2015
Severity of Psoriasis Associates With Aortic Vascular Inflammation Detected by FDG PET/CT and Neutrophil Activation in a Prospective Observational StudyHaley B Naik, Balaji Natarajan, Elena Stansky, et al.
Pageof 11